Distinguished in Laryngeal Cancer

Dr. Christopher E. Lominska

Radiation Oncology
Kansas University Physicians Inc
20333 W 151st St, Olathe Medical Center, 
Olathe, KS 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Offers Telehealth
Distinguished in Laryngeal Cancer
Kansas University Physicians Inc
20333 W 151st St, Olathe Medical Center, 
Olathe, KS 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Christopher Lominska is a Radiation Oncologist in Olathe, Kansas. Dr. Lominska is rated as a Distinguished provider by MediFind in the treatment of Laryngeal Cancer. His top areas of expertise are Laryngeal Cancer, Oral Squamous Cell Carcinoma, Posterior Fossa Tumor, and Bone Tumor. Dr. Lominska is currently accepting new patients.

His clinical research consists of co-authoring 26 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 1 clinical trial in the study of Laryngeal Cancer.

Specialties
Radiation Oncology
Hospital Affiliations
Olathe Medical Center
University Of Kansas Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Home State Health
  • EPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Sunflower Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

KANSAS UNIVERSITY PHYSICIANS INC
20333 W 151st St, Olathe Medical Center, Olathe, KS 66061
Other Locations
KANSAS UNIVERSITY PHYSICIANS INC
4000 Cambridge St, Suite G600, Kansas City, KS 66160
KANSAS UNIVERSITY PHYSICIANS INC
3901 Rainbow Blvd, Suite 5300, Kansas City, KS 66160

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk Features
A Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk Features
Enrollment Status: Recruiting
Publish Date: December 17, 2025
Intervention Type: Procedure, Drug, Radiation, Biological
Study Drugs: Carboplatin, Cisplatin, Pembrolizumab
Study Phase: Phase 2
A Double Blind, Placebo Controlled Dose Range Finding Study to Assess the Safety, Pharmacokinetics, and Efficacy of Tempol for the Reduction of Severe Mucositis in Head and Neck Cancer Patients Undergoing Combined Radio- and Chemotherapy
A Double Blind, Placebo Controlled Dose Range Finding Study to Assess the Safety, Pharmacokinetics, and Efficacy of Tempol for the Reduction of Severe Mucositis in Head and Neck Cancer Patients Undergoing Combined Radio- and Chemotherapy
Enrollment Status: Recruiting
Publish Date: November 20, 2024
Intervention Type: Drug
Study Drug: Tempol
Study Phase: Phase 2
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
Enrollment Status: Completed
Publish Date: December 04, 2025
Intervention Type: Drug, Radiation, Biological
Study Phase: Phase 2
Randomized Phase II/III Trial of Radiation With Cisplatin at 100 mg/m2 Every Three Weeks Versus Radiation With Weekly Cisplatin at 40 mg/m2 for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Randomized Phase II/III Trial of Radiation With Cisplatin at 100 mg/m2 Every Three Weeks Versus Radiation With Weekly Cisplatin at 40 mg/m2 for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Enrollment Status: Suspended
Publish Date: November 07, 2025
Intervention Type: Other, Procedure, Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2/Phase 3
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 31, 2025
Intervention Type: Other, Procedure, Drug, Biological, Radiation
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 2/Phase 3
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Enrollment Status: Completed
Publish Date: September 23, 2025
Intervention Type: Other, Biological, Radiation
Study Drugs: Cetuximab, Durvalumab
Study Phase: Phase 2/Phase 3
A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)
A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)
Enrollment Status: Active_not_recruiting
Publish Date: February 02, 2024
Intervention Type: Procedure, Other, Drug
Study Phase: Phase 2/Phase 3
A Phase I and Expansion Cohort Study of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC)
A Phase I and Expansion Cohort Study of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC)
Enrollment Status: Completed
Publish Date: June 10, 2022
Intervention Type: Drug, Other, Radiation, Biological
Study Drugs: Cisplatin, Pembrolizumab
Study Phase: Phase 1
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial of the Effects of GC4419 on Severe Oral Mucositis in Patients Receiving Cisplatin + Intensity-modulated Radiation Therapy (IMRT) for Locally Advanced Non-Metastatic Squamous Cell Carcinoma (SCC) of the Oral Cavity/Oropharynx
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial of the Effects of GC4419 on Severe Oral Mucositis in Patients Receiving Cisplatin + Intensity-modulated Radiation Therapy (IMRT) for Locally Advanced Non-Metastatic Squamous Cell Carcinoma (SCC) of the Oral Cavity/Oropharynx
Enrollment Status: Completed
Publish Date: September 20, 2021
Intervention Type: Radiation, Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

26 Total Publications

Logistic Model in Clinical and Health Research-the Elephant and Blind Men.
Logistic Model in Clinical and Health Research-the Elephant and Blind Men.
Journal: American journal of clinical oncology
Published: September 15, 2025
Similar Doctors
Advanced in Laryngeal Cancer
Dr. Bradley H. Koffman
Radiation Oncology
Advanced in Laryngeal Cancer
Dr. Bradley H. Koffman
Radiation Oncology

Midwest Oncology Associates LLC

3889 S Jackson Dr, 
Independence, MO 
 (28.7 miles away)
816-698-8290
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Bradley Koffman is a Radiation Oncologist in Independence, Missouri. Dr. Koffman is rated as a Distinguished provider by MediFind in the treatment of Laryngeal Cancer. His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Posterior Fossa Tumor, and Anal Cancer. Dr. Koffman is currently accepting new patients.

Advanced in Laryngeal Cancer
Dr. Bhaswanth Dhanireddy
Radiation Oncology
Advanced in Laryngeal Cancer
Dr. Bhaswanth Dhanireddy
Radiation Oncology

Shawnee Mission Medical Center Inc

9100 W 74th St, Ahmg Cardiology At Shawnee, 
Merriam, KS 
 (12.2 miles away)
913-676-2000
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Bhaswanth Dhanireddy is a Radiation Oncologist in Merriam, Kansas. Dr. Dhanireddy has been practicing medicine for over 17 years and is rated as an Advanced provider by MediFind in the treatment of Laryngeal Cancer. His top areas of expertise are Throat Cancer, Laryngeal Cancer, Pleuropulmonary Blastoma, and Breast Cancer. Dr. Dhanireddy is currently accepting new patients.

Advanced in Laryngeal Cancer
Dr. Stephen D. Coon
Radiation Oncology | Radiology
Advanced in Laryngeal Cancer
Dr. Stephen D. Coon
Radiation Oncology | Radiology
1303 Sw First American Pl, 
Topeka, KS 
 (51.8 miles away)
785-234-3451
Languages Spoken:
English
See accepted insurances

Stephen Coon is a Radiation Oncologist and a Radiologist in Topeka, Kansas. Dr. Coon is rated as an Advanced provider by MediFind in the treatment of Laryngeal Cancer. His top areas of expertise are Laryngeal Cancer, Familial Prostate Cancer, Prostate Cancer, and Pleuropulmonary Blastoma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lominska's expertise for a condition
ConditionClose
    View All 24 Advanced Conditions
    View All 51 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile